{"id":18061,"date":"2014-06-05T01:30:00","date_gmt":"2014-06-04T23:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/farmaceutica-bayer-boss-marijn-dekkers-lascia-a-fine-2016\/"},"modified":"2014-06-05T01:30:00","modified_gmt":"2014-06-04T23:30:00","slug":"farmaceutica-bayer-boss-marijn-dekkers-lascia-a-fine-2016","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/farmaceutica-bayer-boss-marijn-dekkers-lascia-a-fine-2016\/","title":{"rendered":"Pharmaceuticals: Bayer boss Marijn Dekkers leaves at the end of 2016"},"content":{"rendered":"<p>&nbsp;<img decoding=\"async\" src=\"http:\/\/si.wsj.net\/public\/resources\/images\/BN-DB409_bayer0_G_20140603113457.jpg\" alt=\"\" \/><\/p>\n<div>\n<p style=\"margin: 0cm 0cm 6pt; background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;\"><span style=\"font-size: x-large;\"><span style=\"font-family: Arial, sans-serif;\">Rome, 5 June. (Adnkronos Salute) \u2013 Bayer&#039;s top desk will be free at the end of 2016: CEO Marijn Dekkers has in fact announced his intention to resign for that period. The German firm noted that &quot;in line with its wishes&quot;, Dekkers&#039; contract will be extended by just two years after the initial five-year period has expired. Dekkers, reports &#039;PharmaTimes&#039;, cited family reasons at the origin of the decision.<\/span><\/span><span style=\"font-family:&quot;Arial&quot;,&quot;sans-serif&quot;\"><\/p>\n<p><\/span><\/p>\n<p style=\"margin: 0cm 0cm 6pt; background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;\"><span style=\"font-size: x-large;\"><span style=\"font-family: Arial, sans-serif;\">From Bayer they specify that, to &quot;ensure continuity in key aspects&quot; of the future development of the company, Werner Baumann, current Chief Financial Officer of the pharmaceutical company, will become Chief Strategy and Portfolio Officer with effect from October 1, and his contract will last until at the end of 2017. Johannes Dietsch will also take over his current position at Baumann. Dekkers&#039; appointment in 2010 caused quite a stir, as the Dutchman was the first non-German director to take over the reins of the Leverkusen-based company.<\/span><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin-top:3.75pt;line-height:21.0pt;mso-outline-level: 1\"><span lang=\"EN\" style=\"font-size:20.0pt;font-family:OpenSansRegular; mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:&quot;Times New Roman&quot;; color:red;letter-spacing:-.7pt;mso-font-kerning:18.0pt;mso-ansi-language:EN; mso-fareast-language:IT\">The CEO of Bayer leaves early, off to the waltz of the armchairs<\/p>\n<p><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom:0cm;margin-bottom:.0001pt;line-height: 13.5pt\"><span lang=\"EN\" style=\"font-size:9.0pt;font-family:OpenSansLightRegular; mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:&quot;Times New Roman&quot;; color:#666666;mso-ansi-language:EN;mso-fareast-language:IT\">Wednesday 4 June 2014<\/span><span lang=\"EN\" style=\"font-size:10.5pt;font-family:OpenSansLightRegular; mso-fareast-font-family:&quot;Times New Roman&quot;;mso-bidi-font-family:&quot;Times New Roman&quot;; color:#595959;mso-ansi-language:EN;mso-fareast-language:IT\"> <\/p>\n<p><\/span><\/p>\n<p class=\"MsoNormal\" style=\"line-height:13.5pt\"><span lang=\"EN\" style=\"font-size: 10.0pt;font-family:OpenSansLightRegular;mso-fareast-font-family:&quot;Times New Roman&quot;; mso-bidi-font-family:&quot;Times New Roman&quot;;color:#595959;mso-ansi-language:EN; mso-fareast-language:IT\">Of <\/span><b><span lang=\"EN\" style=\"font-size:10.0pt; font-family:OpenSansLightRegular;mso-fareast-font-family:&quot;Times New Roman&quot;; mso-bidi-font-family:&quot;Times New Roman&quot;;color:#333333;mso-ansi-language:EN; mso-fareast-language:IT\">Editorial board <\/span><\/b><span lang=\"EN\" style=\"font-size: 10.0pt;font-family:OpenSansLightRegular;mso-fareast-font-family:&quot;Times New Roman&quot;; mso-bidi-font-family:&quot;Times New Roman&quot;;color:#595959;mso-ansi-language:EN; mso-fareast-language:IT\"><br \/> <a href=\"http:\/\/www.aboutpharma.com\/aboutpharma\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color:#333333; text-decoration:none;text-underline:none\">About Pharma and Medical De<\/p><\/div>","protected":false},"excerpt":{"rendered":"<p>&nbsp; Roma, 5 giu. (Adnkronos Salute) &#8211; La scrivania al vertice di Bayer sar&agrave; libera alla fine del 2016: l&#8217;amministratore delegato Marijn Dekkers ha infatti annunciato la sua intenzione di dimettersi per quel periodo. L&#8217;azienda tedesca ha osservato che &quot;in linea con i suoi desideri&quot;, il contratto di Dekkers sar&agrave; prorogato di soli due anni &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-18061","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=18061"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18061\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=18061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=18061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=18061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}